Biogen-Iden (NASDAQ:BIIB) is seeing its shares pummeled in after-hours trading. The company didn’t have another biotech drug crisis though. Biogen had been under a corporate strategic review where it was evaluating strategic alternatives, but…
We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the…
Medarex inc. (NASDAQ: MEDX) is seeing shares slapped in after-hours trading after the company is issuing disappointing news over the hopes for its Ipilimumab Pivotal Trials in patients with Advanced Metastatic Melanoma. Its partner…
Celgene Corp. (NASDAQ:CELG) is seeing the price of its shares crushed today after trial results were shown on Sunday at the 49th annual American Society of Hematology (ASH) Meeting of Celgene’s drug Revlimid as…
James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad in 2008. In early 2004 this stock was above $40 and had enjoyed an…
Bristol-Myers (BMY) showed the world its equivalent of the old Soviet "Five Year Plan" today. All of the talk up front was about becoming "a next-generation BioPharma company that pairs the scale and resources…
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that dosing has commenced in its Phase IIa clinical trial with LX6171. This is an oral drug candidate that is implied for the treatment of cognitive impairment…
Abbott Labs (ABT) which just launched a new stent product, Xience V, has laid off 1,200 people because of slowness in the stent market. Stranger than fiction. According to MarketWatch, Abbott says it expects…
Medarex, Inc. (Nasdaq: MEDX) this morning has announced the allowance of two separate investigational new drug applications filed with the FDA for MDX-1342: one for the treatment of chronic lymphocytic leukemia (CLL); and the…
Boston Scientific (BSX) has been the leader in sales of stents, those little mess tubes that keep arteries open. Recent studies show that the devices are more dangerous than most doctors had believed. That…
Bronchus Technologies, Inc. filed yesterday for an initial public offering of up to $86.25 million for filing purposes. It has the proposed ticker of "LUNG" on NASDAQ, and the lead underwriters are Lehman Brothers…
Aegerion Pharmaceuticals, Inc. filed Tuesday for an initial public offering of up to $86.25 million in securities for filing purposes. It has the proposed ticker of "AEGR" on NASDAQ, and the underwriting group consists…
Pfizer (NYSE:PFE) is seeing additional pressure this afternoon. Apparently the FDA said it is looking into reports that Pfizer has sent out an "early communications notice" to doctors warning them to monitor patients using…
Quality Systems, Inc. (NASDAQ:QSII) has issued a release stating that it received a letter dated November 19, 2007, from the Securities and Exchange Commission (L.A. regional office) that informed CFO Paul Holt that the…
Now that the FDA has forced GlaxoSmithKline (GSK) to put a "black label" on its diabetes drug Avandia, the competition is going for a coup de grace. Takeda Pharmaceutical Co Ltd said on Thursday…